These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 32827729)

  • 1. Canakinumab Lacks Efficacy in Treating Adult Patients with Moderate to Severe Chronic Spontaneous Urticaria in a Phase II Randomized Double-Blind Placebo-Controlled Single-Center Study.
    Maul JT; Distler M; Kolios A; Maul LV; Guillet C; Graf N; Imhof L; Lang C; Navarini AA; Schmid-Grendelmeier P
    J Allergy Clin Immunol Pract; 2021 Jan; 9(1):463-468.e3. PubMed ID: 32827729
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Benralizumab does not elicit therapeutic effect in patients with chronic spontaneous urticaria: results from the phase IIb multinational randomized double-blind placebo-controlled ARROYO trial.
    Altrichter S; Giménez-Arnau AM; Bernstein JA; Metz M; Bahadori L; Bergquist M; Brooks L; Ho CN; Jain P; Lukka PB; Rodriguez-Suárez E; Walton C; Datto CJ;
    Br J Dermatol; 2024 Jul; 191(2):187-199. PubMed ID: 38367194
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting histamine receptor 4 in cholinergic urticaria with izuforant (LEO 152020): results from a phase IIa randomized double-blind placebo-controlled multicentre crossover trial.
    Grekowitz E; Metz M; Altrichter S; Bauer A; Brockow K; Heine G; Lionnet L; Saday KK; Hultsch T; Søerensen OE; Maurer M
    Br J Dermatol; 2024 May; 190(6):825-835. PubMed ID: 38308655
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of canakinumab in Schnitzler syndrome: A multicenter randomized placebo-controlled study.
    Krause K; Tsianakas A; Wagner N; Fischer J; Weller K; Metz M; Church MK; Maurer M
    J Allergy Clin Immunol; 2017 Apr; 139(4):1311-1320. PubMed ID: 27658762
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sustained remission of symptoms and improved health-related quality of life in patients with cryopyrin-associated periodic syndrome treated with canakinumab: results of a double-blind placebo-controlled randomized withdrawal study.
    Koné-Paut I; Lachmann HJ; Kuemmerle-Deschner JB; Hachulla E; Leslie KS; Mouy R; Ferreira A; Lheritier K; Patel N; Preiss R; Hawkins PN;
    Arthritis Res Ther; 2011; 13(6):R202. PubMed ID: 22152723
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of omalizumab on angioedema in H1 -antihistamine-resistant chronic spontaneous urticaria patients: results from X-ACT, a randomized controlled trial.
    Staubach P; Metz M; Chapman-Rothe N; Sieder C; Bräutigam M; Canvin J; Maurer M
    Allergy; 2016 Aug; 71(8):1135-44. PubMed ID: 27010957
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Omalizumab vs. placebo in the management of chronic idiopathic urticaria: a systematic review.
    Carrillo DC; Borges MS; García E; Egea E; Serrano CD
    World Allergy Organ J; 2014; 7(1):72. PubMed ID: 25566332
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rupatadine is effective in the treatment of chronic spontaneous urticaria in children aged 2-11 years.
    Potter P; Mitha E; Barkai L; Mezei G; Santamaría E; Izquierdo I; Maurer M
    Pediatr Allergy Immunol; 2016 Feb; 27(1):55-61. PubMed ID: 26267219
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hydroxychloroquine in the treatment of anti-histamine refractory chronic spontaneous urticaria, randomized single-blinded placebo-controlled trial and an open label comparison study.
    Boonpiyathad T; Sangasapaviliya A
    Eur Ann Allergy Clin Immunol; 2017 Sep; 49(5):220-224. PubMed ID: 28884989
    [No Abstract]   [Full Text] [Related]  

  • 10. Effectiveness, safety, and tolerability of bilastine 20 mg vs levocetirizine 5 mg for the treatment of chronic spontaneous urticaria: A double-blind, parallel group, randomized controlled trial.
    Podder I; Das A; Ghosh S; Biswas D; Sengupta S; Chowdhury SN
    Dermatol Ther; 2020 Nov; 33(6):e13946. PubMed ID: 32618048
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Omalizumab in patients with symptomatic chronic idiopathic/spontaneous urticaria despite standard combination therapy.
    Kaplan A; Ledford D; Ashby M; Canvin J; Zazzali JL; Conner E; Veith J; Kamath N; Staubach P; Jakob T; Stirling RG; Kuna P; Berger W; Maurer M; Rosén K
    J Allergy Clin Immunol; 2013 Jul; 132(1):101-9. PubMed ID: 23810097
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of bilastine in Japanese patients with chronic spontaneous urticaria: A multicenter, randomized, double-blind, placebo-controlled, parallel-group phase II/III study.
    Hide M; Yagami A; Togawa M; Saito A; Furue M
    Allergol Int; 2017 Apr; 66(2):317-325. PubMed ID: 27599913
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of an Oral CRTh2 Antagonist (AZD1981) on Eosinophil Activity and Symptoms in Chronic Spontaneous Urticaria.
    Oliver ET; Chichester K; Devine K; Sterba PM; Wegner C; Vonakis BM; Saini SS
    Int Arch Allergy Immunol; 2019; 179(1):21-30. PubMed ID: 30879003
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Randomized, double-blind, placebo-controlled study of safety and efficacy of miltefosine in antihistamine-resistant chronic spontaneous urticaria.
    Magerl M; Rother M; Bieber T; Biedermann T; Brasch J; Dominicus R; Hunzelmann N; Jakob T; Mahler V; Popp G; Schäkel K; Schlingensiepen R; Schmitt J; Siebenhaar F; Simon JC; Staubach P; Wedi B; Weidner C; Maurer M
    J Eur Acad Dermatol Venereol; 2013 Mar; 27(3):e363-9. PubMed ID: 22928719
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of omalizumab in Japanese and Korean patients with refractory chronic spontaneous urticaria.
    Hide M; Park HS; Igarashi A; Ye YM; Kim TB; Yagami A; Roh J; Lee JH; Chinuki Y; Youn SW; Lee SK; Inomata N; Choi JH; Fukunaga A; Wang J; Matsushima S; Greenberg S; Khalil S
    J Dermatol Sci; 2017 Jul; 87(1):70-78. PubMed ID: 28366435
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ligelizumab for Chronic Spontaneous Urticaria.
    Maurer M; Giménez-Arnau AM; Sussman G; Metz M; Baker DR; Bauer A; Bernstein JA; Brehler R; Chu CY; Chung WH; Danilycheva I; Grattan C; Hébert J; Katelaris C; Makris M; Meshkova R; Savic S; Sinclair R; Sitz K; Staubach P; Wedi B; Löffler J; Barve A; Kobayashi K; Hua E; Severin T; Janocha R
    N Engl J Med; 2019 Oct; 381(14):1321-1332. PubMed ID: 31577874
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of rupatadine in Japanese adult and adolescent patients with chronic spontaneous urticaria: A double-blind, randomized, multicenter, placebo-controlled clinical trial.
    Hide M; Suzuki T; Tanaka A; Aoki H
    Allergol Int; 2019 Jan; 68(1):59-67. PubMed ID: 30029967
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy of switching to bilastine, a histamine H1 receptor antagonist, in patients with chronic spontaneous urticaria (H1-SWITCH): study protocol for a randomized controlled trial.
    Fukunaga A; Oda Y; Washio K; Omori T; Kakei Y; Hide M; Nishigori C
    Trials; 2020 Jan; 21(1):23. PubMed ID: 31906999
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adjunctive canakinumab reduces peripheral inflammation markers and improves positive symptoms in people with schizophrenia and inflammation: A randomized control trial.
    Weickert TW; Jacomb I; Lenroot R; Lappin J; Weinberg D; Brooks WS; Brown D; Pellen D; Kindler J; Mohan A; Wakefield D; Lloyd AR; Stanton C; O'Donnell M; Liu D; Galletly C; Shannon Weickert C
    Brain Behav Immun; 2024 Jan; 115():191-200. PubMed ID: 37848096
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Remibrutinib, a novel BTK inhibitor, demonstrates promising efficacy and safety in chronic spontaneous urticaria.
    Maurer M; Berger W; Giménez-Arnau A; Hayama K; Jain V; Reich A; Haemmerle S; Lheritier K; Walsh P; Xia S; Storim J
    J Allergy Clin Immunol; 2022 Dec; 150(6):1498-1506.e2. PubMed ID: 36096203
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.